To our knowledge, this is the first study involving CXCR4-targeted protein nanoparticles for the treatment of HNSCC metastatic development, which holds great promise as a future therapy for HNSCC patients. The gene discussed is CXCR4; the disease is head and neck squamous cell carcinoma.